Abbott Laboratories (ABT) Cost of Revenue (2016 - 2026)

Abbott Laboratories' Cost of Revenue history spans 18 years, with the latest figure at $4.9 billion for Q1 2026.

On a quarterly basis, Cost of Revenue rose 9.44% to $4.9 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $19.7 billion, a 5.5% increase, with the full-year FY2025 number at $19.3 billion, up 3.28% from a year prior.
Cost of Revenue hit $4.9 billion in Q1 2026 for Abbott Laboratories, down from $4.9 billion in the prior quarter.
Over the last five years, Cost of Revenue for ABT hit a ceiling of $5.1 billion in Q3 2025 and a floor of $4.3 billion in Q1 2023.
Historically, Cost of Revenue has averaged $4.7 billion across 5 years, with a median of $4.6 billion in 2022.
Biggest five-year swings in Cost of Revenue: increased 13.32% in 2022 and later fell 13.15% in 2023.
Tracing ABT's Cost of Revenue over 5 years: stood at $4.6 billion in 2022, then dropped by 0.81% to $4.6 billion in 2023, then grew by 8.47% to $4.9 billion in 2024, then decreased by 0.4% to $4.9 billion in 2025, then dropped by 0.65% to $4.9 billion in 2026.
Business Quant data shows Cost of Revenue for ABT at $4.9 billion in Q1 2026, $4.9 billion in Q4 2025, and $5.1 billion in Q3 2025.

Peer Comparison